Skip to content

Hypertensive treatment in elderly with cerebral small vessel disease: should we SPRINT faster?

Hypertensive treatment in elderly with cerebral small vessel disease: should we SPRINT faster? - Treatment of hypertension in elderly with CSVD

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON47398
Enrollment
20
Registered
2018-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension High Blood Pressure

Interventions

The intervention group will be treated using SPRINT-targets (SBP *120mmHg) and the control group using conventional blood pressure targets (SBP
Cerebral Bloof Flow (CBF)
Cerebral Small Vessel disease (CSVD)
Hemodynamics
Hypertension

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - * 65 years of age - High systolic blood pressure of 150-200 mmHg assessed with a daytime 24-hour BP (with or without taking antihypertensive medication) - Cerebral small vessel disease (white matter lesions; Fazekas score * 2) on MRI

Exclusion criteria

Exclusion criteria: - Diabetes mellitus - Experienced myocardial infarction within the past 12 months - Medical history of stroke in the past 6 months or large (sub) cortical cerebral infarction on MRI - Medical history of end stage heart failure (NYHA III-IV) - Stage 4-5 kidney failure - Clinical Dementia Rating (CDR) scale>1 - Life expectancy less than 1 year - Unable to obtain an optimal window for TCD measurements - Significant stenosis (>70%) of the left of right common carotid artery

Design outcomes

Primary

MeasureTime frame
The primary outcome measures are: CBF (static and dynamic) velocity measured with Transcranial Doppler (TCD).

Secondary

MeasureTime frame
Secondary outcome measures are: cognitive functioning, degree of white matter lesions. orthostatic hypotension, cerebral autoregulatory capacity, CO2 responsiveness, premature trial termination because of unacceptable drug side effects.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)